Wells Fargo Maintains Overweight on Monte Rosa Therapeutics, Lowers Price Target to $27
Benzinga Newsdesk 3 months ago
NewsPrice TargetAnalyst Ratings
Wells Fargo analyst Derek Archila maintains Monte Rosa Therapeutics (NASDAQ:GLUE) with a Overweight and lowers the price target from $29 to $27.
Wells Fargo analyst Derek Archila maintains Monte Rosa Therapeutics (NASDAQ:GLUE) with a Overweight and lowers the price target from $29 to $27.